Drug Profile
Research programme: herpes simplex virus DNA replication inhibitors - ViRAZE
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer ViRAZE
- Class Antivirals; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections(Treatment-resistant) in USA
- 14 Jan 2019 Preclinical trials in Herpes simplex virus infections are still ongoing in USA (unspecified route) (Virez pipeline, January 2019)